GlassScriptPhysician profile
Steve A Siegler
NPI 1366439739
$6,691.47
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $1,147 · 2021: $1,488 · 2022: $1,527 · 2023: $956 · 2024: $79.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,649.50 | 2019-2024 | Rybelsus, Ozempic, Saxenda |
| Astrazeneca Pharmaceuticals LP | $712.91 | 2019-2023 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $672.27 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Medtronic Vascular, INC. | $552.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.80 | 2019-2022 | |
| Amarin Pharma, INC. | $394.81 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $370.45 | 2019-2023 | |
| Medtronic, INC. | $366.42 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Abbvie INC. | $358.57 | 2021-2023 | Ubrelvy, Qulipta |
| Amgen INC. | $357.63 | 2019-2023 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $170.09 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $105.83 | 2019-2023 | |
| Abbott Laboratories | $66.58 | 2023 | Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $62.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.14 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.89 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $46.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.90 | 2020-2021 | |
| Philips North America LLC | $28.77 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.49 | 2020 | |
| Boston Scientific Corporation | $25.58 | 2022 | |
| Zyla Life Sciences, INC. | $25.18 | 2020 | |
| Harmony Biosciences LLC | $22.93 | 2022 | |
| Dexcom, INC. | $19.09 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.84 | 2021 | |
| Radius Health, INC. | $16.46 | 2020 | |
| Gilead Sciences, INC. | $15.83 | 2020 | |
| Genentech USA, INC. | $12.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.39 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.32 | 2021 | |
| Allergan, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Siegler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.